Anti-CAR Antibodies May Undermine Cell Therapy in Brain Tumors
Chimeric antigen receptor T-cell therapies for brain tumors have shown limited durability, in part because of an antibody attack on the engineered receptor itself, new research shows. Suppressing that response, either with preconditioning drugs or by redesigning the chimeric antigen receptor, helps make the cells and their therapeutic benefit last.
Publication Details
- Journal
- Cancer Discovery
- Published
- 2026-11-12
- DOI
- https://doi.org/10.1158/2159-8290.cd-nw2026-0106
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00